There’s a ground-breaking new therapy for small cell lung cancer that’s under consideration by the FDA and EMA that promises to become the new gold standard
You may have already heard about Tecentriq, the new therapy for small cell lung cancer (SCLC) that’s all the buzz, and for a good reason — it’s the first drug in over two decades that’s shown survival benefits in extensive-stage SCLC.
This remarkable new therapy is promising to replace the current standard of care for extensive stage lung cancer in cancer centres across the globe. The results of the IMpower133 study entered into the lung cancer conversation at the 19th World Conference on Lung Cancer in September 2018. The study compared Tecentriq (atezolizumab) plus chemotherapy to chemotherapy alone. The incredible overall survival and progression-free survival rates and manageable safety profile of the Tecentriq group stood out in a big way to medical oncologists. Based on these results the FDA has granted a priority review designation for Tecentriq for use in combination with chemotherapy for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
There’s a high unmet need in extensive-stage lung cancer. Although patients may respond to chemotherapy, they quickly relapse and only 2% are alive at 5 years after diagnosis. Tecentriq is a big breakthrough, and it’s offering hope.
Making an Impact
With rapid advancements in oncology, health care practitioners know that keeping up with new research keeps them on the cutting edge and enables them to provide the best possible treatments to their patients. Getting the word out about new innovations is crucial. Depending on your marketing, communications, or education needs, there may be an opportunity for an innovative education strategy to help bring the latest evidence into practice. We have different solutions that may work for you. Talk to us. We’re here to help.